Novoron Bioscience - About the company
Novoron Bioscience is a seed company based in San Diego (United States), founded in 2013. It operates as a Developer of therapeutics for neurological diseases. Novoron Bioscience has raised $15.1M in funding from Two Bear Capital. The company has 2884 active competitors, including 975 funded and 713 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.
Company Details
Developer of therapeutics for neurological diseases. It offer therapies for nerve regeneration in the central nervous system (CNS) specifically, spinal cord injury (SCI).It offer biologic therapeutics to inhibit the LRP1/Rho pathway and, thus, promote neuronal and axonal regeneration.
- Website
- novoron.com
- Social
Key Metrics
Founded Year
2013
Location
San Diego, United States
Stage
Seed
Total Funding
$15.1M in 14 rounds
Latest Funding Round
Investors
Ranked
1263rd among 2884 active competitors
Employee Count
16 as on Aug 31, 2026
Similar Companies
Legal entities associated with Novoron Bioscience
Novoron Bioscience is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
NOVORON BIOSCIENCE, INC. CIN: 464854823 , United Kingdom, Active | - | 11 (As on Dec 31, 2022) |
Sign up to download Novoron Bioscience's company profile
Novoron Bioscience's funding and investors
Novoron Bioscience has raised a total funding of $15.1M over 14 rounds. Its first funding round was on Jul 01, 2014. Its latest funding round was a Seed round on Mar 2026 for $*****. 1 investor participated in its latest round. Novoron Bioscience has 7 institutional investors.
Here is the list of recent funding rounds of Novoron Bioscience:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 2026 | 2193268 | Seed | 9391383 | 3648249 | 7345849 | 3589027 |
Sep 16, 2025 | 7265238 | Grant (prize money) | 2875497 | 8660108 | 5511973 | |
Feb 03, 2025 | 1288010 | Grant (prize money) | 7160676 | 9349738 | 5600812 |
Access funding benchmarks and valuations. Sign up today!View details of Novoron Bioscience's funding rounds and investors
Novoron Bioscience's founders and board of directors
Founder? Claim ProfileNovoron Bioscience's employee count trend
Novoron Bioscience has 16 employees as of Aug 26. Here is Novoron Bioscience's employee count trend over the years:
Uncover Novoron Bioscience's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Novoron Bioscience's Competitors and alternates
Top competitors of Novoron Bioscience include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Novoron Bioscience, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
1263rd | Novoron Bioscience 2013, San Diego (United States), Seed | Developer of therapeutics for neurological diseases | $15.1M | 35/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Novoron Bioscience's competitors? Click here to see the top ones
Novoron Bioscience's Investments and acquisitions
Novoron Bioscience has made no investments or acquisitions yet.
Reports related to Novoron Bioscience
Here is the latest report on Novoron Bioscience's sector:
News related to Novoron Bioscience
•
Novoron Bioscience Awarded NIH Grant for Research Into Alzheimer's DiseasePR Newswire•Jan 28, 2022•Novoron Bioscience
•
Novoron Bioscience Raises $3M in Seed Financing from Two Bear CapitalPR Newswire•Nov 16, 2021•Novoron Bioscience
•
Backstage Capital backs Native American-run biotech firm NovoronImpactAlpha•Mar 03, 2018•Backstage, Novoron Bioscience, Backstage Capital
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Novoron Bioscience
Explore our recently published companies
- Ben Aipa Surfboards - Honolulu based, Unfunded company
- Bragan - Ireland based, 2007 founded, Unfunded company
- Hotel Dom - Switzerland based, 1998 founded, Unfunded company
- Utechia - Istanbul based, 2019 founded, Public company
- Karmly - Wellington based, 2016 founded, Unfunded company
- Mobile Wala - Unfunded company
